Hudson Bay Capital Management LP Trims Stock Holdings in Genmab A/S Sponsored ADR $GMAB

Hudson Bay Capital Management LP lowered its stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 11.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 265,000 shares of the company’s stock after selling 35,000 shares during the period. Hudson Bay Capital Management LP’s holdings in Genmab A/S were worth $8,128,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GMAB. Creative Planning lifted its holdings in Genmab A/S by 11.8% in the 2nd quarter. Creative Planning now owns 65,132 shares of the company’s stock valued at $1,346,000 after purchasing an additional 6,870 shares in the last quarter. Rockefeller Capital Management L.P. purchased a new stake in shares of Genmab A/S during the second quarter worth about $267,000. JPMorgan Chase & Co. grew its holdings in shares of Genmab A/S by 17.0% during the second quarter. JPMorgan Chase & Co. now owns 933,309 shares of the company’s stock worth $19,282,000 after buying an additional 135,814 shares in the last quarter. Brandywine Global Investment Management LLC raised its position in shares of Genmab A/S by 1.6% in the second quarter. Brandywine Global Investment Management LLC now owns 1,744,769 shares of the company’s stock valued at $36,047,000 after buying an additional 27,372 shares during the last quarter. Finally, AlphaCore Capital LLC acquired a new position in shares of Genmab A/S in the second quarter valued at approximately $44,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on GMAB. Wall Street Zen lowered shares of Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Morgan Stanley assumed coverage on Genmab A/S in a report on Monday, February 16th. They issued an “equal weight” rating and a $34.00 price target for the company. Guggenheim reduced their price target on Genmab A/S from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, February 23rd. Jefferies Financial Group initiated coverage on Genmab A/S in a report on Tuesday, February 17th. They set a “buy” rating and a $41.50 price objective on the stock. Finally, Wells Fargo & Company assumed coverage on Genmab A/S in a research report on Monday, March 2nd. They issued an “overweight” rating and a $40.00 price objective for the company. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.58.

Genmab A/S Price Performance

Genmab A/S stock opened at $25.10 on Friday. Genmab A/S Sponsored ADR has a 1 year low of $17.24 and a 1 year high of $35.43. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.01 and a current ratio of 2.02. The firm has a 50 day moving average price of $30.19 and a 200 day moving average price of $30.49. The company has a market cap of $16.13 billion, a price-to-earnings ratio of 16.19, a PEG ratio of 1.05 and a beta of 0.94.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Tuesday, February 17th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. The company had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.06 billion. Sell-side analysts predict that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

Genmab A/S Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.